acute myeloid leukemia
Conditions
Interventions
HMAs Group:Demethylated drug
Sponsors
Children's Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. 0-18 years old. 2. Children with high-risk or relapsed AML after transplantation. 3. Obtain the consent of the child or/and the Guardian and sign the informed consent form. 4. Expected survival time greater than 3 months.
Exclusion criteria
Exclusion criteria: 1. Failure of Hematopoietic stem cell transplantation. 2. Hematopoietic or extramedullary relapse after Hematopoietic Stem Cell Transplantation. 3. Do not receive systematic demethylated drug therapy as part of the treatment regimen. 4. Patients can not be rid of transfusion dependence, have uncontrolled infection or grade III/IV acute GVHD (GVHD according to WHO criteria) . 5. Severe Heart, lung, kidney, and liver dysfunction, poor nutritional status, and inability to tolerate demethylation therapy; 6. Patients with severe infection who can not tolerate demethylating agents; 7. Any significant abnormality of co-existing diseases or mental disorders affects the patient's life safety and compliance, informed consent, study participation, follow-up or interpretation of results. In this case, all participants are required to report directly to the project manager and jointly decide whether the exclusion criteria are met. 8. The researchers evaluated other reasons for not being selected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DFS;CR;ORR; | — |
Countries
China
Contacts
Public ContactHu Shaoyan
Children's Hospital of Soochow University
Outcome results
None listed